Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ICL670, deferoxamine · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| ICL670 + deferoxamine | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| ICL670, deferoxamine | DRUG | - |
Inclusion Criteria: * Age greater than or equal to 2 years * Sickle cell disease patients already treated with or suitable for treatment with deferoxamine 20 to 40 mg/kg/day * Serum ferritin greater than 1000 mg/ml * Liver iron content greater than 2 mg iron/g dw assessed by means of superconductin...
ICL670 is an investigational small molecule being developed for beta-thalassemia, sickle cell disease, anemia, sickle cell, and transfusional iron overload. It is studied in patients with iron overload due to blood transfusions, including those with beta-thalassemia and sickle cell disease.
ICL670 is being developed by Novartis AG, a multinational pharmaceutical company traded on the New York Stock Exchange under the ticker symbol NVS. The company is conducting clinical trials to evaluate the safety and efficacy of ICL670 in patients with transfusional iron overload.
ICL670 is in Phase 3 clinical development. One Phase 3 trial has been completed, along with several Phase 2 trials. The drug is investigational and has not been approved by regulatory authorities, as it remains under clinical investigation.
ICL670 has been studied in several completed trials. NCT00061750 is a Phase 3 trial in beta-thalassemia patients with iron overload. NCT00067080 and NCT01090323 are Phase 2 trials in sickle cell disease. NCT01044186 is a Phase 2 trial for patients with life-threatening complications of transfusional iron overload.
In clinical trials, ICL670 has been compared to deferoxamine, an active control. The Phase 3 trial NCT00061750 evaluated safety and efficacy of ICL670 versus deferoxamine in beta-thalassemia patients. Other trials also used deferoxamine as a comparator in sickle cell disease and iron overload settings.